OncoMatch

OncoMatch/Clinical Trials/NCT06810375

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

Is NCT06810375 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) and Intercostal nerve block for lung cancers.

Phase 3RecruitingGeorge Washington UniversityNCT06810375Data as of May 2026

Treatment: Erector Spinae (ESP) Block with Bupivacaine (Marcaine®) · Intercostal nerve blockThis clinical trial compares efficacy in postoperative pain management in thoracic surgery between erector spinae block versus liposomal bupivacaine injections.

Check if I qualify

Eligibility summary

For patients with lung carcinoma.

This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.

US trial sites

  • The George Washington University Hospital · Washington D.C., District of Columbia

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify